Vitamin D deficiency and a CYP27B1–1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

Lange, CM; Bojunga, Jörg; Ramos-Lopez, E.; Wagner, M. von; Hassler, Angela; Vermehren, Johannes; Herrmann, E.; Badenhoop, Klaus; Zeuzem, Stefan; Sarrazin, C

doi:10.1055/s-0030-1263902

Cited by 60 publications

(133 citation statements)

References 0 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…[6] A few studies have recently reported the association of serum vitamin D levels with fibrosis levels and response to treatment in genotypes 1,2,3 HCV. [7][8][9] Some other studies, however, have negated such evidence. [10] Two small trials have reported an improved SVR with vitamin D supplementation.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D Receptor FokI Gene Polymorphism Predicted Poor Response to Treatment in Chronic HCV Genotype 4

Shehab¹,

Sabry²,

Mukhtar³

et al. 2016

Int J Biomed

View full text Add to dashboard Cite

The aim of this study was to investigate the association between a genetic polymorphism of the vitamin D receptor (VDR) and antiviral responses in Egyptian patients with chronic hepatitis C virus genotype 4 (HCV-4). Methods: Our study enrolled 100 HCV-4 patients who received pegylated interferon alpha-2a (pegIFNα-2a) and ribavirin for 48 weeks. Patients were divided into 2 groups according to their response to therapy: 50 were responders, and 50 were nonresponders. All HCV-4 patients were further subjected to the following laboratory tests: HCV-RNA using quantitative PCR, vitamin D level using ELISA and VDR genotype using PCR-RFLP assays, and abdominal ultrasonography.Results: There was a statistically significant difference in the frequency of the VDR polymorphism (FokI rs10735810) between responders (FF:60%, Ff:16%, ff:24%) and non-responders (FF:10%, Ff:26%, ff:64%) (P<0.001). There was a statistically significant association between VDR polymorphism with higher ALT levels (ff: 63.2±30

show abstract

Section: Introductionmentioning

confidence: 99%

Vitamin D Receptor FokI Gene Polymorphism Predicted Poor Response to Treatment in Chronic HCV Genotype 4

Shehab¹,

Sabry²,

Mukhtar³

et al. 2016

Int J Biomed

View full text Add to dashboard Cite

show abstract

“…Vitamin D is an important immune modulator and preliminary data indicated an association between vitamin D deficiency and SVR rates in HCV as reduced 25-hydroxyvitamin D levels and CYPB27-1260 promotor polymorphism with reduced 1,25-dihydroxyvitamin D levels are associated with failure to achieve SVR in HCV genotypes 1-, 2-, and 3-infected patients [9,25] . Our HCV patients with genotype IV need further follow up to confirm the effect of vitamin D deficiency on their responses to treatment.…”

mentioning

confidence: 99%

Relationship between vitamin D and IL-23, IL-17 and macrophage chemoattractant protein-1 as markers of fibrosis in hepatitis C virus Egyptians

Husseiny

Fahmy²,

Mohamed³

et al. 2012

WJH

View full text Add to dashboard Cite

AIM:To assess vitamin D in hepatitis C patients and its relationship to interleukin (IL)-23, IL-17, and macrophage chemoattractant protein-1 (MCP-1). METHODS:The study was conducted on 50 Egyptian hepatitis C virus (HCV) genotype number IV-infected patients and 25 age-and gender-matched healthy subjects. Venous blood samples were obtained. Samples were allowed to clot and sera were separated by centrifugation and stored at -20 ℃. A 25 hydroxy vitamin D assay was carried out using solid phase RIA. A 1,25 dihydroxy vitamin D assay was carried out using a commercial kit purchased from Incstar Corporation. IL-17 and -23 and MCP-1 were assayed by an enzyme immunoassay. Quantitative and qualitative polymerase chain reaction for HCV virus were done by TaqMan technology. Only HCV genotype IV-infected subjects were included in the study. The mean ± SD were determined, a t -test for comparison of means of different parameters was used. Correlation analysis was done using Pearson's correlation. Differences among different groups were determined using the Kruskal-Wallis test. RESULTS:The mean vitamin D level in HCV patients (group Ⅰ) was 15 ± 5.2 ng/mL while in control (group Ⅱ) was 39.7 ± 10.8. For active vitamin D in group Ⅰ as 16.6 ± 4.8 ng/mL while in group Ⅱ was 41.9 ± 7.9. IL-23 was 154 ± 97.8 in group Ⅰ and 6.7 ± 2.17 in group Ⅱ. IL-17 was 70.7 ± 72.5 in cases and 1.2 ± 0.4 in control. MCP-1 was 1582 ± 794.4 in group Ⅰ and 216.1 ± 5.38 in group Ⅱ. Vitamin D deficiency affected 72% of HCV-infected patients and 0% of the control group. Vitamin D insufficiency existed in 28% of HCV-infected patients and 12% of the control group. One hundred percent of the cirrhotic patients and 40% of non cirrhotic HCV-infected patients had vitamin D deficiency. IL-23, IL-17, and MCP-1 were markedly increased in HCV-infected patients in comparison to controls.A significant negative correlation between vitamin D and IL-17 and -23 and MCP-1 was detected. HCV-infected males and females showed no differences with respect to viral load, vitamin D levels, IL-17, IL-23 and MCP-1. The viral load was negatively correlated with vitamin D and active vitamin D (P = 0.0001 and P = 0.001, respectively), while positively correlated with IL-23, IL-17, and MCP-1. We classified the patients according to sonar findings into four groups. Group Ⅰa with bright hepatomegaly and included 14 patients. Group Ⅰb with perihepatic fibrosis and included 11 patients. Group Ⅰc with liver cirrhosis and included 11 patients. Group Ⅰd with hepatocellular carcinoma (HCC) and included 14 patients. Vitamin D and active vitamin D were shown to be lower in cirrhotic patients and much lower in patients with HCC, and this difference was highly significant (P = 0.0001). IL-17 and -23 and MCP-1 were higher in advanced liver disease) and the differences were highly significant (P = 0.0001). ORIGINAL ARTICLE

show abstract

“…Some studies show that vitamin D serum levels are inversely related to liver fibrosis, showing a relationship between the anti-inflammatory effects (10,14,20) . Thus, vitamin D deficiency could contribute to a (5) .…”

Section: Discussionmentioning

confidence: 99%

Is there an association between vitamin D and liver fibrosis in patients with chronic hepatitis C?

Oliveira

Buss

Tovo

2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND Vitamin D is known for its immunomodulatory, anti-inflammatory and antifibrotic properties, which are quite relevant in the pathogenesis and treatment of many causes of chronic liver disease. OBJECTIVE This study aimed to evaluate the association between serum vitamin D levels and the histopathological findings in patients with chronic hepatitis C virus infection. METHODS Cross-sectional study composed of patients with chronic hepatitis C. All patients underwent vitamin D 25 dosage and anthropometric data analysis. Liver biopsy was performed in a maximum 36-month period before inclusion in the study. RESULTS Of the 74 patients included in the study, 45 (60.8%) were women, mean age was 57.03±9.24 years, and 63 (85.1%) were white. No association was observed between the serum levels of vitamin D and inflammatory activity (P=0.699) nor with the degree of liver fibrosis (P=0.269). CONCLUSION In this study, no association was observed between vitamin D and inflammatory activity, as well as the degree of liver fibrosis, in patients with chronic hepatitis C.

show abstract

Vitamin D deficiency and a CYP27B1–1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

Cited by 60 publications

References 0 publications

Vitamin D Receptor FokI Gene Polymorphism Predicted Poor Response to Treatment in Chronic HCV Genotype 4

Vitamin D Receptor FokI Gene Polymorphism Predicted Poor Response to Treatment in Chronic HCV Genotype 4

Relationship between vitamin D and IL-23, IL-17 and macrophage chemoattractant protein-1 as markers of fibrosis in hepatitis C virus Egyptians

Is there an association between vitamin D and liver fibrosis in patients with chronic hepatitis C?

Contact Info

Product

Resources

About